Matinas Biopharm - MTNB STOCK NEWS

Matinas BioPharma Holdings announced the topline results for its ENHANCE-IT study, comparing LYPDISO™ against Vascepa®. Key findings showed a 46% relative increase in EPA levels and a 39% reduction in triglycerides (TGs) versus Vascepa, although the latter did not meet statistical significance. However, LYPDISO™ demonstrated significant reductions in several lipid and inflammatory markers in the per-protocol population. The study involved 100 participants and aimed to assess cardiovascular risk reduction potential.

Matinas BioPharma (NYSE: MTNB) announces CEO Jerome D. Jabbour will present a company overview at the ICR Conference 2021 on January 14, 2021, at 1:00 p.m. ET. He will also host virtual investor meetings. Investors can access a live webcast on the Company’s IR Calendar page, with a replay available for 90 days post-event. Matinas focuses on developing innovative therapeutics, including LYPDISO™, which targets hypertriglyceridemia, and MAT2203, an antifungal treatment currently in clinical trials. The Company’s technology aims to improve drug delivery and efficacy.

Matinas BioPharma Holdings (MTNB) announced that the FDA has conditionally accepted LYPDISO as the proposed brand name for its drug MAT9001, targeting cardiovascular and metabolic conditions. Additionally, the USPTO granted a Notice of Allowance for the trademark registration of LYPDISO. The company is preparing to submit a New Drug Application and expects topline data from its head-to-head study against Vascepa® in Q1 2021, with Phase 3 trials starting in H2 2021. These developments are significant for the potential commercialization of MAT9001.

Matinas BioPharma (MTNB) announced a collaboration with the National Institute of Allergy and Infectious Diseases (NIAID) to explore oral formulations of remdesivir using its Lipid Nanocrystal (LNC) delivery platform. This collaboration aims to develop formulations that might enhance drug delivery capabilities, particularly in combating COVID-19. Gilead Sciences will provide remdesivir, while Matinas will utilize NIAID’s preclinical services to conduct antiviral testing. The outcome of this partnership could provide significant advancements in oral drug administration for critical therapies.

Matinas BioPharma Holdings (MTNB) announced a Special Meeting of Stockholders on January 26, 2021, to seek approval for a potential reverse stock split of its common stock, within a range of 1-for-2 to 1-for-15. This initiative aims to enhance the stock's appeal to institutional investors and possibly facilitate inclusion in biotechnology and pharmaceutical indices, while positioning the company for an uplisting to major exchanges like NYSE or NASDAQ. The final split ratio will be determined by the Board after stockholder approval.

Matinas BioPharma Holdings, Inc. (MTNB) has appointed Hui Liu, Ph.D., M.B.A. as the new Chief Technology Officer. With over 20 years of experience in pharmaceutical development, particularly in lipid-based delivery systems, Dr. Liu aims to enhance the company's proprietary lipid nanocrystal (LNC) platform. Previously at Seqirus, he has expertise in lipid nanoparticle technologies for gene therapies. The company continues to advance its lead product, MAT9001, targeting hypertriglyceridemia, and is also developing MAT2203 and MAT2501 for serious infections and antibiotic treatments, respectively.

Matinas BioPharma (MTNB) has secured an award of up to $3.75 million from the Cystic Fibrosis Foundation to support the preclinical development of MAT2501, an oral formulation of amikacin targeting nontuberculous mycobacterial lung disease. The funding aims to accelerate MAT2501's advancement through essential studies towards Phase 2 trials. FDA designations as QIDP and Orphan Drug for MAT2501 offer potential marketing exclusivity for up to 12 years upon approval. The company is focused on addressing unmet medical needs in the treatment of chronic infections.

Matinas BioPharma Holdings, Inc. (NYSE: MTNB) will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference from December 1-3, 2020. The company is set to host investor meetings and will have a pre-recorded fireside chat available on their website starting November 23, 2020. Matinas is focused on developing therapeutics for unmet medical needs, with its lead product candidate, MAT9001, targeting hypertriglyceridemia. Additionally, MAT2203, aimed at treating invasive fungal infections, is currently in a Phase 2 study for HIV-infected patients.

Matinas BioPharma Holdings (NYSE: MTNB) reported progress in its clinical studies and financial results for Q3 2020. The EnACT study of MAT2203 for cryptococcal meningitis received a recommendation from the DSMB to proceed to the second cohort, with evaluations set for mid-2021. Enrollment in the ENHANCE-IT study of MAT9001 against Vascepa is complete, and topline data is expected in Q1 2021. The company ended the quarter with $62.8 million in cash and a net loss of $5.7 million. Management remains focused on advancing its drug candidates and anticipates sufficient funds for operations through H1 2023.